학술논문
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Document Type
Article
Author
Qin, Shukui; Chen, Minshan; Cheng, Ann-Lii; Kaseb, Ahmed O; Kudo, Masatoshi; Lee, Han Chu; Yopp, Adam C; Zhou, Jian; Wang, Lu; Wen, Xiaoyu; Heo, Jeong; Tak, Won Young; Nakamura, Shinichiro; Numata, Kazushi; Uguen, Thomas; Hsiehchen, David; Cha, Edward; Hack, Stephen P; Lian, Qinshu; Ma, Ning; Spahn, Jessica H; Wang, Yulei; Wu, Chun; Chow, Pierce K H; Thompson, Alexander; Danta, Mark; Poursoltan, Pirooz; Kiberu, Andrew; Chittajallu, Renuka; Sood, Siddarth; Stauber, Rudolf; Pinter, Matthias; Peck-Radosavljevic, Markus; Decaestecker, Jochen; Cuyle, Pieter-Jan; Verset, Gontran; Van Vlierberghe, Hans; De Azevedo, Sergio; Andrade, Livia; Cunha Júnior, Ademar; Faria, Luiza; Yen, Cheng Tzu; Colli, Leandro; Asselah, Jamil; Kavan, Petr; Marquez, Vladimir; Brahmania, Mayur; Li, Qiang; Xing, Baocai; Guo, Yabing; Chen, Zhendong; Zhao, Haitao; Peng, Tao; Wang, Liming; Wang, Lu; Liu, Hongming; Wu, Feixiang; Qin, Lunxiu; Zheng, Qichang; Ying, Jieer; Li, Haitao; Wen, Tianfu; Qin, Shukui; Wen, Xiaoyu; Liu, Yunpeng; Chen, Minshan; Wang, Boqing; Bai, Yuxian; He, Yifu; Zhao, Hong; Zhou, Dong; Dai, Chaoliu; Teng, Gaojun; Cui, Shuzhong; Gao, Yi; Zhang, Xizhi; Lu, Zheng; Yin, Tao; Ding, Youming; Jia, Weidong; Xia, Yongxiang; Sun, Beicheng; Xia, Qiang; Yuan, Yufeng; Sun, Huichuan; Shi, Xuetao; Guzmán, Adrián; Corrales, Luis; Kral, Zdenek; Priester, Peter; Kubala, Eugen; Blanc, Jean Frederic; Bourliere, Marc; Peron, Jean Marie; Borg, Christophe; Bronowicki, Jean-Pierre; Ganne, Nathalie; Decaens, Thomas; Uguen, Thomas; Heurgue, Alexandra; Trojan, Joerg; Gonzalez-Carmona, Maria Angeles; Roderburg, Christoph; Ettrich, Thomas; Schotten, Clemens; Kandulski, Arne; Yau, Thomas; Chan, Lam; Scartozzi, Mario; Masi, Gianluca; Fanello, Silvia; Battezzati, Pier Maria; Leonardi, Francesco; Ghidini, Michele; Numata, Kazushi; Morimoto, Manabu; Hidaka, Hisashi; Tsuchiya, Kaoru; Yamashita, Tatsuya; Kato, Naoya; Kudo, Masatoshi; Hagihara, Atsushi; Koga, Hironori; Arakawa, Tomohiro; Nakamura, Ikuo; Kawamura, Yusuke; Kawaoka, Tomokazu; Shimada, Mitsuo; Hasegawa, Kiyoshi; Marusawa, Hiroyuki; Nakamura, Shinchiro; Hiraoka, Atsushi; Hayashi, Hiromitsu; Takeda, Shin; Lee, Han Chu; Paik, Seung Woon; Kim, Do Young; Lee, Jung Il; Jeong, Sook-Hyang; Kim, Won; Tak, Won Young; Heo, Jeong; Kim, Hyeyeong; Chon, Hong Jae; Cheong, Jaeyoun; Yoon, Seung Kew; Yoon, Jung-Hwan; Villalobos, Ricardo; Martinez Rodriguez, Jorge Luis; Oyervides Juarez, Victor; Hernández, Carlos Alberto; Klumpen, Heinz-Josef; de Vos-Geelen, Judith; Gane, Edward; Montenegro, Paola; Torres Mattos, Cesar; Janczewska, Ewa; Kawecki, Maciej; Nowakowska-Zajdel, Ewa; Fedenko, Alexander; Granov, Dmitrii; Alyasova, Anna; Sekacheva, Marina; Ledin, Evgeny; Samol, Jens; Toh, Han Chong; Calvo Campos, Mariona; Gomez Martin, Carlos; Lopez Lopez, Carlos; Muñoz Martin, Andres Jesus; Calleja Panero, Jose Luis; Montero Alvarez, Jose Luis; Reig Monzón, Maria; Delgado Mingorance, Ignacio; Minguez Rosique, Beatriz; Cheng, Ann Lii; Huang, Yi-Hsiang; Lin, Shi-Ming; Huang, Jee-Fu; Yu, Ming-Lung; Su, Wei-Wen; Korphaisarn, Krittiya; Maneenil, Kunlatida; Samdaengpan, Chayanee; Tharavichitkul, Ekkapong; Ozguroglu, Mustafa; Kose, Fatih; Harputluoglu, Hakan; Buchschacher, Gary; Thuluvath, Paul; Xiong, Henry; Patel, Mital; Gold, Philip; Li, Daneng; Brooks, Gabriel; Masood, Ashiq; Patel, Reema; George, Ben; Salgia, Reena; Manji, Gulam; Crow, Mary; Kaseb, Ahmed; Dugan, Matthew; Kadakia, Kunal; Kardosh, Adel; Gibbs, John; Shah, Ashesh; Burris III, Howard; Hsiehchen, David
Source
The Lancet; November 2023, Vol. 402 Issue: 10415 p1835-1847, 13p
Subject
Language
ISSN
01406736; 1474547X
Abstract
No adjuvant treatment has been established for patients who remain at high risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We aimed to assess the efficacy of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with high-risk hepatocellular carcinoma.